ATE132374T1 - Verhütung und behandlung einer retrovirenkrankheit - Google Patents

Verhütung und behandlung einer retrovirenkrankheit

Info

Publication number
ATE132374T1
ATE132374T1 AT88906347T AT88906347T ATE132374T1 AT E132374 T1 ATE132374 T1 AT E132374T1 AT 88906347 T AT88906347 T AT 88906347T AT 88906347 T AT88906347 T AT 88906347T AT E132374 T1 ATE132374 T1 AT E132374T1
Authority
AT
Austria
Prior art keywords
immunogen
retrovirus
hiv
infectious
useful
Prior art date
Application number
AT88906347T
Other languages
English (en)
Inventor
Jonas Salk
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Application granted granted Critical
Publication of ATE132374T1 publication Critical patent/ATE132374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
AT88906347T 1987-06-10 1988-06-09 Verhütung und behandlung einer retrovirenkrankheit ATE132374T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6028087A 1987-06-10 1987-06-10
US20075288A 1988-05-31 1988-05-31

Publications (1)

Publication Number Publication Date
ATE132374T1 true ATE132374T1 (de) 1996-01-15

Family

ID=26739775

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88906347T ATE132374T1 (de) 1987-06-10 1988-06-09 Verhütung und behandlung einer retrovirenkrankheit

Country Status (14)

Country Link
EP (3) EP0317622B1 (de)
JP (1) JPH0720880B2 (de)
AT (1) ATE132374T1 (de)
AU (1) AU612383B2 (de)
CA (1) CA1336407C (de)
DE (1) DE3854857T2 (de)
DK (1) DK56389D0 (de)
FI (1) FI95871C (de)
IL (1) IL86675A (de)
NO (1) NO175846C (de)
OA (1) OA09037A (de)
RU (1) RU2111010C1 (de)
UA (1) UA27716C2 (de)
WO (1) WO1988009670A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU620804B2 (en) * 1987-03-23 1992-02-27 Hiver Limited Novel vaccines
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
EP0474868B1 (de) * 1989-05-30 1996-11-13 Nippon Zeon Co., Ltd. Verfahren zur herstellung von kernstrukturen von retroviren und dadurch hergestellte partikel
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
AU4685293A (en) * 1992-07-20 1994-02-14 Immune Response Corporation, The Prophylactic and therapeutic control of retroviral infections
CA2186034C (en) * 1994-03-22 2002-11-26 Michael E. Hrinda Highly efficient production and isolation of viral particles
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
DK507185A (da) * 1984-11-05 1986-05-06 Du Pont Fremgangsmaade til inaktivering af human tumor leukaemi virus iii
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
WO1986006099A1 (en) * 1985-04-08 1986-10-23 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
DK171119B1 (da) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
EP0249611A4 (de) * 1985-11-14 1988-04-26 Harvard College T-lymphotrophisches virus.
EP0250128A3 (de) * 1986-06-18 1988-06-08 American Registry of Pathology Von AIDS-Patienten isoliertes Virus
CA1341277C (en) * 1987-03-16 2001-07-31 Roland Keith Mcgready Anti-paratopic antibody and a method of its manufacture

Also Published As

Publication number Publication date
AU612383B2 (en) 1991-07-11
EP0602761A1 (de) 1994-06-22
EP0685236A1 (de) 1995-12-06
CA1336407C (en) 1995-07-25
EP0317622A4 (de) 1990-05-14
DE3854857T2 (de) 1996-08-22
JPH0720880B2 (ja) 1995-03-08
NO890565L (no) 1989-02-09
OA09037A (en) 1991-03-31
FI95871C (fi) 1996-04-10
IL86675A (en) 1993-04-04
NO175846C (no) 1994-12-21
AU1962688A (en) 1989-01-04
DK56389A (da) 1989-02-08
FI890603A (fi) 1989-02-08
RU2111010C1 (ru) 1998-05-20
WO1988009670A1 (en) 1988-12-15
EP0317622B1 (de) 1996-01-03
NO890565D0 (no) 1989-02-09
DE3854857D1 (de) 1996-02-15
NO175846B (de) 1994-09-12
EP0317622A1 (de) 1989-05-31
FI95871B (fi) 1995-12-29
FI890603A0 (fi) 1989-02-08
DK56389D0 (da) 1989-02-08
JPH02500440A (ja) 1990-02-15
UA27716C2 (uk) 2000-10-16

Similar Documents

Publication Publication Date Title
RU94042386A (ru) Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
DE69737736D1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
ATE418562T1 (de) Ctl epitope des epstein-barr virus
EP0330359A3 (de) Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion
OA08652A (fr) Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus.
EP1375511A3 (de) Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
DE3854857T2 (de) Verhütung und behandlung einer retrovirenkrankheit
ATE188484T1 (de) Immunologisch mit hla homologe hiv protein epitope
ATE108335T1 (de) Kit oder zusammensetzung zur vorbeugung oder behandlung von hiv-1 infektionen.
FR2385401A1 (fr) Vaccin a virus respiratoire syncytial
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
DE69707680T2 (de) Caprin arthritis-enzephalitis virus enthaltende vakzine und verwendung zur immunschutz gegen hiv-1 infektion
ITRM950209A1 (it) Vaccino per la profilassiimmunitaria dell'infezione da virus della immunodeficienza felina del gatto domestico.
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
HUP0202389A2 (hu) Macskafélék calicivírus-betegsége elleni, inaktivált vakcina
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
EP0309898A3 (de) Methode zur Induktion einer zytotoxischen T-Zell-Antwort
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
RU1801212C (ru) Способ отбора детей из группы риска дл ревакцинации против кори
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
RU98105627A (ru) Вакцины

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee